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ABSTRACT Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients
but it is not known whether it is associated with worse clinical outcomes independent of the underlying
severity of disease.
This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis
clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa
chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and
mortality was assessed.
The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P. aeruginosa was associated with
a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53–2.66;
p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98;
95% CI 0.70–1.36; p=0.89). P. aeruginosa was independently associated with increased mortality only in
patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36–3.03; p=0.001). An
independent association with worse quality of life of 7.46 points (95% CI 2.93–12.00; p=0.001) was found
in a multivariable linear regression. P. aeruginosa was therefore found to be independently associated with
exacerbation frequency, hospital admissions and worse quality of life. Mortality was increased in patients
with P. aeruginosa particularly in the presence of frequent exacerbations.
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Introduction
Bronchiectasis is a chronic and progressive respiratory disease characterised by permanent dilation of
bronchi, impairment of mucus clearance, chronic cough and sputum production, and an increased
frequency of respiratory infections [1]. Without effective mucociliary and innate antimicrobial defences,
there is a higher risk of chronic bacterial infection of the airways, which can lead to an increase in airway
inflammation and structural damage [2, 3].
Pseudomonas aeruginosa is one of the most important organisms causing chronic infection in
bronchiectasis, because of its capacity to maintain virulence despite antibiotic therapies by forming
biofilms and easily developing antimicrobial resistance [4–6]. P. aeruginosa in cystic fibrosis (CF)
bronchiectasis is associated with a steeper decrease in lung function and increased morbidity and mortality
[7]. Its presence in bronchiectasis seems to be linked with a more severe disease, but whether there is a
direct effect on disease progression or whether P. aeruginosa is just an indicator of existing clinical severity
remains a topic of discussion [8–10].
In a recent meta-analysis, P. aeruginosa chronic infection was related to a threefold increase in mortality,
as well as a higher risk of hospital admissions and increased exacerbation frequency [11]. This study
however, was not able to take into account the multiple confounders that are usually present in more
severe bronchiectasis patients and that could play a role in mortality, such as forced expiratory volume in
1 s (FEV1), comorbidities or severe exacerbations. Moreover, there was some heterogeneity in terms of
chronic infection definition and measured parameters across the different studies [11]. To definitively
answer whether P. aeruginosa directly drives disease progression and mortality in bronchiectasis would
require a longitudinal study able to identify the point at which P. aeruginosa infection first occurs and to
compare morbidity before and after acquisition. As such studies are not currently available, an alternative
method is to utilise multivariable modelling, which allows the estimation of the independent contribution
of P. aeruginosa after removing the effects of confounding variables.
The rate of P. aeruginosa chronic infection in bronchiectasis patients varies among the studies, between 9–
31%, and its prevalence in a large, multicentre population from several different countries is yet to be
assessed [12–18].
The aim of this study was to assess the burden of disease in P. aeruginosa chronic infection and its
independent impact in terms of patient outcomes.
Methods
This study analysed data from bronchiectasis patients enrolled in 10 different bronchiectasis clinical centres
across Europe (including Israel as an EU affiliated country) (Dundee, Edinburgh, Newcastle – UK; Haifa –
Israel; Galway – Ireland; Leuven – Belgium; Athens – Greece; Monza – Italy; Barcelona – Spain; Vojvodina –
Serbia) between 2007 and 2013. Consecutive patients aged ⩾18 years with a diagnosis of bronchiectasis, made
by a specialist physician, based on a high-resolution computed tomography scan and with a compatible
clinical history (defined by the presence of respiratory symptoms attributable to bronchiectasis) were enrolled.
Patients had to be free from antibiotic treatment for exacerbation for 4 weeks prior to enrolment and initial
data collection. Patients with CF or traction bronchiectasis because of pulmonary fibrosis were excluded,
and also patients with active nontuberculous mycobacterial (NTM) disease. The local ethics committee or
institutional review board approved the data collection at each site. Diagnostic work-up and assessment
were made following algorithms consistent with the 2010 British Thoracic Society (BTS) guidelines [19].
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Identification of microorganisms and susceptibility testing were performed according to standard methods
[20]. Chronic infection was defined by isolation of the same pathogen in two or more cultures, at least
3 months apart in a 12-month period [19].
Demographics, previous medical history, comorbidities as well as radiological, laboratory and
microbiological findings were obtained from a combination of direct patient history, medical records and
laboratory information recorded at each site. Quality of life (QoL) was measured by the St George’s
Respiratory Questionnaire (SGRQ), and severity of disease was evaluated by the Bronchiectasis Severity
Index (BSI) [21]. There was a follow-up period of 5 years, in which exacerbations and hospitalisations were
recorded, following BTS guidelines definitions, and mortality was assessed.
Statistical analysis
Simple descriptive statistics of mean with standard deviation (SD) were used for continuous parametric
data, median with 25–75% interquartile range (IQR) for continuous nonparametric data, and frequencies
and percentages for categorical data. Subgroup comparisons were performed using the unpaired t-test,
Mann–Witney U-Test or Chi-squared test, depending on data distribution.
Kaplan–Meier curves were used to illustrate survival data. For multivariable mortality analysis, Cox
proportional hazard regression analysis was performed to estimate hazard ratios (HRs) and their 95%
confidence intervals (CI). Variables included in the model were those determined by the investigators to
be clinically significant in impacting on mortality. In a sensitivity analysis, changes in prophylactic
antibiotic therapy during the study were examined as a confounder in a Cox proportional hazard
regression with treatment as a time-varying covariate.
A multiple linear regression model was applied to determine the variables with an independent impact on
QoL. To check the suitability of our model, we fitted a generalised linear model (GLM) with
quasibinomial errors and a logit link. The signs and significance of every estimated parameter in this
matched its equivalent in the linear model. Estimates of the change in fitted values, from the GLM, on
stepping one unit away from the centre of the dataset (the medians of all numerical values) in each
direction all fell within the 95% CI around the betas in the linear model. However, while the model results
are very similar, the terms within the generalised linear model are difficult to interpret. We have, therefore,
described the results of the linear model.
All analyses were performed using SPSS version 21 (SPSS, Chicago, IL, USA) for Windows platform and
Graph Pad Prism Version 5 (Graph Pad Software, San Diego, CA, USA).
Results
Patient characteristics
The study population was composed of 2596 patients. Individual inclusion per site was 608 in Edinburgh,
504 in Dundee, 116 in Newcastle, 280 in Galway, 190 in Leuven, 113 in Vojvodina, 88 in Haifa, 159 in
Athens, 198 in Barcelona and 340 in Monza.
The patient characteristics are described in detail in table 1.
The median age was 67 years (IQR 57–74 years) and there was a female predominance (61.1%, n=1586).
In terms of comorbidities, the highest reported conditions were ischaemic heart disease, 17.5% (n=453),
chronic obstructive pulmonary disease (COPD), 16.6% (n=431), gastro-oesophageal reflux disease
(GORD), 15.2% (n=394) and diabetes, 10.0% (n=260). The median BSI score was 6 (IQR 4–10) with a
homogeneous distribution between the severity groups: mild (0–4) (29.0%, n=753), moderate (5–8)
(35.7%, n=927), severe (⩾9) (35.3%, n=916). Patients had a median of 41.2 points in the SGRQ (IQR
24.5–59.6). Most patients were classified as idiopathic (42%), with post-infective aetiology (17%), COPD
(9%), asthma (6%), connective tissue diseases (6%) and allergic bronchopulmonary aspergillosis (5%) also
being common in this cohort.
At the time of enrolment, the median number of exacerbations in the previous year was two (IQR 0–3);
however, 37.2% (n=966) had three or more exacerbations over the same period, and 25.9% (n=672) had at
least one hospitalisation in the previous year.
Pseudomonas aeruginosa chronic infection prevalence
Half of the study population had a chronic respiratory infection with at least one pathogen (50.4%,
n=1307). The most common were Haemophilus influenzae (21.9%, 95% CI 20.4–23.6%, n=569) and
P. aeruginosa (15.0%, 95% CI 13.7–16.4%, n=389). Rates of P. aeruginosa infection varied across different
European centres, from the lowest in Serbia 0.9% (95% CI 0.2–4.8%), Belgium 8.4% (95% CI 5.3–13.2%),
Italy 12.1% (95% CI 9.0–15.9%), UK 12.5% (95% CI 10.7–14.4%) and Ireland 13.9% (95% CI 10.4–18.5%)
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to the highest rates in Spain 21.2% (95% CI 16.1–27.4%), Greece 36.5% (95% CI 29.4–44.2%) and Israel
44.3% (95% CI 34.4–54.7%). Active NTM was excluded, but NTM isolation as baseline was reported in 46
subjects.
Patient characteristics according to chronic infection status
Patients with P. aeruginosa were slightly older (median (IQR), 70 years (59–77 years) versus 67 years (57–
74 years) versus 66 years (57–75 years), p<0.001) and had a lower FEV1% (57.9% versus 69.2% versus
77.0%, p<0.001) than patients chronically infected with other pathogens or those not chronically infected
respectively (table 3). They had more major cardiovascular comorbidities such as ischaemic heart disease
and stroke. They had also more exacerbations on the previous year (median (IQR) 3 (2–4) versus 2 (1–3)
versus 1 (0–2), p<0.001) and a higher percentage of patients with at least one hospital admission in the
previous year (59.9% versus 31.9% versus 17.6%, p<0.000). The median BSI was higher in the P. aeruginosa
group (median (IQR) 13 (10–17) versus 8 (5–13) versus 5 (3–8), p<0.001). Data are presented in table 2.
Mortality analysis
There were 281 deaths during the follow-up period, which accounted for 10.8% (95% CI 9.7–12.1%) of the
total study population. There were 73 deaths in 389 patients (18.8%) in the P. aeruginosa chronic infection
group, 75 in 918 (8.2%) in the other pathogens chronic infection group and 133 in 1289 (10.3%) in
patients with no chronic infection (p<0.0001 comparing all three groups).
TABLE 1 Patient characteristics
Patients 2596 (100%)
Demographics
Age years 67 (57–74)
⩾65 years old 1395 (53.7%)
Male 1010 (38.9%)
BMI kg·m−2 24.8 (21.8–28.1)
Smokers and ex-smokers 990 (38.1%)
Comorbidities
Ischaemic heart disease 453 (17.5%)
Stroke 152 (5.9%)
Diabetes 260 (10.0%)
Liver disease 41 (1.6%)
Chronic renal failure 154 (5.9%)
COPD 431 (16.6%)
Asthma 226 (8.7%)
Connective tissue disease 210 (8.1%)
Neurological disease 68 (2.6%)
Osteoporosis 192 (7.4%)
GORD 394 (15.2%)
Haematological malignancy 33 (1.3%)
Solid tumour 164 (6.3%)
Functional status
FEV1 % predicted 73.8 (54.0–92.1)
FEV1 <50% predicted 502 (19.3%)
Clinical status
Number of exacerbations in the previous year 2 (0–3)
Three or more exacerbations per year 966 (37.2%)
At least one hospitalisation in the previous year 672 (25.9%)
Disease severity
BSI score 6 (4–10)
Mild BSI score# 753 (29.0%)
Moderate BSI score¶ 927 (35.7%)
Severe BSI score+ 916 (35.3%)
Quality of life
SGRQ§ 41.2 (24.5–59.6)
Data are presented as median (interquartile range) unless otherwise stated. BMI: body mass index; COPD:
chronic obstructive pulmonary disease; GORD: gastro-oesophageal reflux disease; FEV1: forced expiratory
volume in 1 s; BSI: Bronchiectasis Severity Index; SGRQ: St George’s Respiratory Questionnaire. #: BSI 0–4;
¶: BSI 5–8; +: BSI >9; §: n=987.
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A univariate analysis of the impact P. aeruginosa chronic infection had in terms of mortality showed a
higher mortality in the P. aeruginosa group than in all the other patients (HR 2.02; 95% CI 1.53–2.66;
p<0.0001) (figure 1).
A multivariate analysis was then performed with the variables that were determined to be clinically
relevant affecting mortality (table 3). These results show that the presence of a P. aeruginosa chronic
infection in isolation does not have an independent impact in terms of mortality (HR 0.98; 95% CI 0.70–
1.36; p=0.89). Other variables however, such as age (HR 1.05; 95% CI 1.04–1.07; p<0.001), exacerbation
frequency (HR (per exacerbation) 1.06; 95% CI 1.01–1.12; p=0.02) and hospitalised exacerbations (HR
1.60; 95% CI 1.17–2.19; p=0.003) had an independent contribution to a higher mortality.
We hypothesised that mortality associated with P. aeruginosa chronic infection may be exacerbation
dependent. A separate analysis in terms of mortality was made dividing the study population into four
categories: 1) P. aeruginosa chronic infection with less than two exacerbations per year; 2) P. aeruginosa
chronic infection with two or more exacerbations per year; 3) no P. aeruginosa and less than two
exacerbations per year; 4) no P. aeruginosa and two or more exacerbations per year.
Patients with P. aeruginosa and two or more exacerbations per year had a higher mortality rate (20.5%),
followed by patients with frequent exacerbations without P. aeruginosa (12.5%). In those with fewer than
two exacerbations per year, the mortality rate in the presence of P. aeruginosa chronic infection was 9.7%
versus 6.7% in those without P. aeruginosa chronic infection. Of note, only 62 out of 389 patients with
P. aeruginosa had fewer than two exacerbations per year.
Survival curves of the four groups are presented in figure 2.
A multivariate analysis was performed using the same variables. Having P. aeruginosa chronic infection
with fewer than two exacerbations had no impact in terms of mortality (HR 0.90; 95% CI 0.39–2.12;
TABLE 2 Differences between patients with chronic Pseudomonas aeruginosa infection, chronic infection by other pathogens
and no chronic infection
P. aeruginosa chronic infection Other pathogen chronic infection No chronic infection p-value
Patients 389 (15.0%) 918 (35.4%) 1289 (49.7%)
Demographics
Age years 70 (59–77) 67 (57–74) 66 (57–75) <0.001
⩾65 years old 244 (62.7%) 685 (74.6%) 674 (52.3%) <0.001
Male 167 (42.9%) 522 (41.7%) 468 (36.3%) <0.001
BMI kg·m−2 24.9 (21.3–27.7) 24.6 (21.4–27.7) 25.2 (22.3–28.4) <0.001
Smokers and ex-smokers 122 (31.4%) 457 (49.8%) 516 (40.0%) <0.001
Comorbidities
Ischaemic heart disease 64 (16.5%) 251 (20.0%) 190 (14.7%) <0.001
Stroke 30 (7.7%) 79 (6.3%) 69 (5.4%) 0.009
Diabetes 53 (13.6%) 115 (9.2%) 137 (10.6%) 0.18
Chronic renal failure 23 (5.9%) 61 (4.9%) 88 (6.8%) 0.82
COPD 78 (20.1%) 196 (15.7%) 229 (17.8%) 0.10
Haematological malignancy 9 (2.3%) 22 (1.8%) 11 (0.9%) 0.009
Solid tumour 27 (6.9%) 88 (7.0%) 71 (5.5%) 0.001
Functional status
FEV1 % predicted 57.9 (42–77.7) 69.2 (50–89.8) 77.0 (59–95) <0.001
FEV1 <50% predicted 135 (34.7%) 290 (31.6%) 200 (15.5%) <0.001
Clinical status
Exacerbations in the previous year 3 (2–4) 2 (1–3) 1 (0–2) <0.001
At least one hospitalisation in the
previous year
233 (59.9%) 400 (31.9%) 227 (17.6%) <0.001
Disease severity
BSI score 13 (10–17) 8 (5–13) 5 (3–8) <0.001
Mild BSI score# 0 (0%) 209 (22.8%) 543 (42.1%) <0.001
Moderate BSI score¶ 54 (13.9%) 461 (50.2%) 458 (35.5%) <0.001
Severe BSI score+ 335 (86.1%) 581 (63.3%) 288 (22.3%) <0.001
Quality of life
SGRQ 58.7 (42.0–79.3)§ 44.5 (26.8–62.6)ƒ 35.6 (21.0–52.3)## <0.001
Data are presented as median (interquartile range) unless otherwise stated. BMI: body mass index; COPD: chronic obstructive pulmonary
disease; FEV1: forced expiratory volume in 1 s; BSI: Bronchiectasis Severity Index; SGRQ: St George’s Respiratory Questionnaire. #: BSI 0–4;
¶: BSI 5–8; +: BSI >9; §: n=125; ƒ: n=517; ##: n=345.
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p=0.81). Patients having two or more exacerbations per year had increased mortality (HR 1.74; 95% CI
1.28–2.38; p<0.001) an effect that was magnified in the presence of P. aeruginosa (HR 2.03; 95% CI 1.36–
3.03; p=0.001).
A sensitivity analysis accounting for the centre as an independent variable in the analysis did not affect the
conclusions (HR 1.09, 95% CI 0.78–1.53; p=0.6) in the fully adjusted analysis. The same was observed in
the analysis of subgroups by exacerbation history: P. aeruginosa plus a history of two exacerbations per
year (HR 2.22, 95% CI 1.44–3.43, p<0.0001), two or more exacerbations per year without P. aeruginosa
(HR 1.88, 95% CI 1.34–2.60, p<0.0001). P. aeruginosa without a history of frequent exacerbations was not
associated with mortality (HR 0.90, 95% CI 0.38–2.12, p=0.8). Finally, in a sensitivity analysis including
changes in treatment during follow-up as a time varying covariate, no differences in the conclusions were
found. HRs were P. aeruginosa plus a history of two exacerbations per year (HR 2.01, 95% CI 1.26–3.22,
FIGURE 1 Kaplan–Meier log-rank
test survival curve and univariate
analysis for mortality: chronic
Pseudomonas aeruginosa (PA)
infection versus all other patients.
Cox proportional hazard regression
analysis. Hazard ratio for death for
chronic PA infection 2.02 (95% CI
1.53–2.66, p<0.001).
95
100
90
85
80
75
70
Su
rv
iv
al
 %
Follow-up years
0 1 2 3 4 5
PA
No-PA
TABLE 3 Multivariate Cox regression analysis of factors associated with survival
Variable Hazard ratio for death (95% CI) p-value
Chronic Pseudomonas aeruginosa infection 0.98 (0.70–1.36) 0.89
Age years 1.05 (1.04–1.07) <0.001
Male sex versus female 1.29 (0.99–1.67) 0.06
MRC dyspnoea score 1.25 (1.11–1.40) <0.001
FEV1 % predicted
<30 1.00 (ref.) NA
30–49 0.66 (0.43–0.99) 0.05
50–79 0.44 (0.29–0.68) <0.001
⩾80 0.45 (0.28–0.73) 0.001
Hospitalised exacerbations 1.60 (1.17–2.19) 0.003
Radiology score# 1.02 (0.99–1.06) 0.17
BMI <18.5 kg·m−2 1.70 (1.14–2.54) 0.01
Smoking status 1.14 (0.86–1.50) 0.37
Exacerbations in the previous year per additional
exacerbation
1.06 (1.01–1.12) 0.02
Chronic Haemophilus influenzae infection 0.59 (0.40–0.86) 0.007
Chronic Staphylococcus aureus infection 1.69 (1.10–2.60) 0.02
Chronic Moraxella catarrhalis infection 0.72 (0.39–1.33) 0.30
Chronic Enterobacteriaceae infection 0.71 (0.44–1.15) 0.16
COPD 1.41 (1.04–1.90) 0.03
Diabetes 1.27 (0.92–1.75) 0.14
Chronic renal failure 1.46 (1.03–2.06) 0.03
Ischaemic heart disease 1.47 (1.12–1.93) 0.006
Oral long-term antibiotic suppressive therapy 1.11 (0.84–1.47) 0.46
Nebulised long-term antibiotic suppressive therapy 0.80 (0.51–1.25) 0.33
MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s; BMI: body mass index; COPD:
chronic obstructive pulmonary disease; NA: not applicable. #: Reiff score.
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p=0.003), two or more exacerbations per year without P. aeruginosa (HR 1.80, 95% CI 1.27–2.55,
p=0.001). P. aeruginosa without a history of frequent exacerbations was not associated with mortality (HR
0.82, 95% CI 0.32–2.09, p=0.7). New antibiotic treatment (oral or inhaled) during follow-up was not
significantly associated with mortality HR 0.78, 95% CI 0.46–1.34, p=0.4 (table 4).
TABLE 4 Multivariate Cox regression analysis of factors associated with survival after
categorisation into four new groups
Variable Hazard ratio for death (95% CI) p-value
Groups
No chronic Pseudomonas aeruginosa infection with <2
exacerbations per year
1.00 (ref.) NA
No chronic Pseudomonas aeruginosa infection with ⩾2
exacerbations per year
1.74 (1.28–2.38) <0.001
Chronic Pseudomonas aeruginosa infection with <2
exacerbations per year
0.90 (0.39–2.12) 0.81
Chronic Pseudomonas aeruginosa infection with ⩾2
exacerbations per year
2.03 (1.36–3.03) 0.001
Age years 1.05 (1.04–1.07) <0.001
Male sex versus female 1.29 (1.00–1.68) 0.055
Radiology score# 1.03 (0.99–1.06) 0.11
BMI <18.5 kg·m−2 1.68 (1.13–2.50) 0.011
Smoking status 1.11 (0.84–1.47) 0.45
MRC dyspnoea score 1.24 (1.16–1.45) <0.001
FEV1 % predicted
<30 1.00 (ref.) NA
30–49 0.66 (0.44–1.00) 0.048
50–79 0.41 (0.27–0.62) <0.001
⩾80 0.43 (0.27–0.68) <0.001
Chronic Haemophilus influenzae infection 0.57 (0.39–0.84) 0.005
Chronic Staphylococcus aureus infection 1.73 (1.10–2.60) 0.01
Chronic Moraxella catarrhalis infection 0.78 (0.43–1.44) 0.43
Chronic Enterobacteriaceae infection 0.78 (0.49–1.24) 0.29
COPD 1.33 (0.98–1.81) 0.07
Diabetes 1.28 (0.93–1.75) 0.13
Chronic renal failure 1.58 (1.13–2.23) 0.008
Ischemic heart disease 1.46 (1.11–1.92) 0.007
Oral long-term antibiotic suppressive therapy 1.14 (0.86–1.49) 0.36
Nebulised long-term antibiotic suppressive therapy 0.79 (0.51–1.25) 0.32
BMI: body mass index; MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s; COPD:
chronic obstructive pulmonary disease; NA: not applicable. #: Reiff score.
FIGURE 2 Kaplan–Meier log-rank
test survival curve: comparison
between four groups: chronic
Pseudomonas aeruginosa (PA)
infection with fewer than two
exacerbations per year; chronic PA
infection with two or more
exacerbations per year; no PA and
fewer than two exacerbations per
year; and no PA and two or more
exacerbations per year.
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Risk of exacerbations and hospital admissions
P. aeruginosa and H. influenzae chronic infection constituted predictors of future exacerbations: incident
rate ratio (95% CI) 1.14 (1.04–1.27) and 1.13 (1.03–1.24) respectively.
Patients with P. aeruginosa chronic infection had a much higher probability of having a hospital admission
on a univariate analysis (odds ratio (OR): 4.96; 95% CI 3.96–6.22; p<0.001). This effect was also seen,
although to a lesser degree, in a multivariable analysis (OR 2.28; 95% CI 1.69–3.08; p<0.001).
Quality of life analysis
The median value of SGRQ in the P. aeruginosa group was 58.1 points (IQR–54.0–62.2) and was higher
than the median values for the other pathogens and the no chronic infection groups. A multivariable
linear regression was performed showing an independent increase in the SGRQ of 7.46 points (95% CI
2.93–12.00; p=0.001), higher than the minimal clinically important difference (MCID) for SGRQ, which is
4 points [22]. These results were confirmed on the generalised linear model with quasibinomial errors and
a logit link.
Discussion
This is the largest single study of bronchiectasis patients with the aim to assess the prevalence and burden
of P. aeruginosa chronic infection.
While multiple studies have reported an association between P. aeruginosa and more severe bronchiectasis,
and some have shown an association with poorer clinical outcomes, these were predominantly single
centre, with small samples sizes and could not provide any information as to whether P. aeruginosa was a
cause of poor outcomes or simply a marker of more severe disease. Our study contributes to this debate by
clearly demonstrating that after adjustment for multiple possible confounding variables, P. aeruginosa
remains associated with increased exacerbations, increased hospital admission risk and worse QoL. An
association with mortality was only demonstrated in patients experiencing frequent exacerbations.
The prevalence of P. aeruginosa chronic infection in this study population was 15.0%, which is in keeping
with the ranges of prior publications (9–31%) [12–17]. In a recent meta-analysis, FINCH et al. identified a
rate of P. aeruginosa colonisation of 24.1%, but the various studies included had different definitions of
chronic colonisation, with some regarding a single isolate as indicative of chronic infection [11]. Mortality
in this study population, with a follow-up of 5 years, was 10.8%, which is within the range of prior quoted
studies over 4–5 years follow-up (LOEBINGER et al. [12] 9% at 4 years, GOEMINNE et al. [23] 20% at 5 years).
Several studies have identified P. aeruginosa chronic infection as a risk factor for mortality in
bronchiectasis patients [11, 12, 21, 23, 24]. A pooled OR for mortality was 2.95 (95% CI 1.98–4.40;
p<0.0001) in the Finch meta-analysis. In our cohort, for the univariate analysis we had a HR of 2.02 (95%
CI 1.53–2.66; p<0.0001). Because this group of patients has more risk factors than other groups, such as
poorer lung function, increased age, certain comorbidities, it is important to clearly assess if P. aeruginosa
really has an independent impact factor on mortality. In that matter, a multivariate analysis was
performed. Herein independent predictors of mortality were age, low BMI, number of exacerbations, but
in isolation, persistent infection with P. aeruginosa was not.
To better understand why there was such a difference between univariate and multivariate analysis, the
study population was divided into four groups (in terms of P. aeruginosa chronic infection and number of
exacerbations) and a new multivariate analysis was performed. It became clear that having exacerbations
plays a major role in mortality, independent of P. aeruginosa status. These data strengthen the importance
of reducing exacerbations in all bronchiectasis patients, particularly in the case of P. aeruginosa chronic
infection, where a higher mortality risk is seen with frequent exacerbations.
Even allowing for varying thresholds for admission across different healthcare systems, where home
intravenous antibiotic may or may not be available, P. aeruginosa appears strongly correlated with
exacerbation frequency and the risk of hospitalisation. The risk of hospital admission is related to severity
of disease, number of exacerbations and the antibiotic susceptibility pattern of the pathogen responsible
for the exacerbation, which in the case of P. aeruginosa is often limited to intravenous antibiotics.
QoL was evaluated in this study using the SGRQ, which has been extensively validated in bronchiectasis
patients [25]. P. aeruginosa chronic infection has been associated with a lower QoL, and in the FINCH et al.
[11] meta-analysis there was an 18.2 points decrement in the SGRQ [21, 26]. The decrement justified by
the presence of P. aeruginosa chronic infection was of 7.46 points (95% CI 2.93–12.00; p=0.001) which is
considerably lower than the meta-analysis result. However, since it was adjusted for multiple variables, it
gives us a better understanding of the real impact of this chronic infection in QoL, and it is still clearly
clinically significant and far above the MCID for SGRQ.
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If we accept now that there is robust evidence that P. aeruginosa drives worse outcomes in bronchiectasis
there are a number of clinical implications. First, a limited amount of observational data suggest that it
may be possible to prevent P. aeruginosa chronic infection by giving eradication treatment with oral,
intravenous and/or inhaled antibiotics in combination [27]. A conditional recommendation in favour of
this approach was provided in the 2017 ERS bronchiectasis guidelines [28]. Secondly, if P. aeruginosa
infection cannot be prevented, then our data suggest that patients experiencing frequent exacerbations
have the worst outcomes and so exacerbation prevention should be the key therapeutic focus. Long-term
macrolides have been shown to reduce exacerbation frequency in bronchiectasis, but these studies included
few subjects with P. aeruginosa [29]. Inhaled antibiotics such as colistin, aminoglycosides and aztreonam
have been tested in large populations of patients with P. aeruginosa with equivocal results [28]. Larger
studies are awaited. The ERS bronchiectasis guidelines provided a conditional recommendation for the use
of inhaled antibiotics for patients with P. aeruginosa and three or more exacerbations per year, with
macrolides to be added if inhaled antibiotics fail to control exacerbations [28]. Our results reinforce the
importance of following these recommendations alongside optimising airway clearance, vaccination and
the use of pulmonary rehabilitation in these patients [28].
The strengths of this study are the substantial number of patients included, the evaluation at different
bronchiectasis clinical sites in different countries across Europe, and the considerable amount of patient
data collected. A significant number of events, related to the large study population, enabled us to have a
robust multivariate analysis with many variables, which helped to better understand the independent
impact of P. aeruginosa chronic infection. Despite this, we acknowledge that the number of patients with
P. aeruginosa not having frequent exacerbations was low. We cannot exclude the possibility that this group
has an increased risk of death.
The main limitation of this study is not having a description of the cause of death in all cohorts. It would
have been useful to know the number of deaths associated with respiratory causes. Another important
limitation is that P. aeruginosa diagnosis is based on sputum culture, which is known to be insensitive,
and the methods and frequency of sputum culture are not standardised [30]. This could potentially
underestimate the frequency of P. aeruginosa chronic infection. Another limitation is the absence of an
analysis of the impact that the P. aeruginosa phenotype/strain type and resistance pattern could have in
terms of the patient’s outcomes [30].
This study gives us a more accurate view of the real P. aeruginosa chronic infection prevalence across
Europe. It also enables us to better understand its burden of disease, with a connection to poorer lung
function, more exacerbations and hospitalisations, and a worse QoL. In terms of mortality, the relationship
between P. aeruginosa and an increased risk of death, described previously in the literature, seems to be
closely related with the fact that these patients have more exacerbations and more hospitalisations, rather
than just the simple fact of being chronically infected by this pathogen. Our analysis cannot fully account
for the “chicken or egg” question of which characteristic comes first in disease. It is not known whether
patients with P. aeruginosa have more exacerbations and therefore have worse outcomes, or whether
frequently exacerbating patients have a poor prognosis with frequent antibiotic courses leading to
P. aeruginosa infection and poor outcomes. Our study can only demonstrate that the combination of these
two parameters increases mortality. The mechanism by which exacerbations contribute to increase
mortality in bronchiectasis is not fully understood and should be the subject of detailed translational
research. Our work could have major implications for healthcare policy; it implies that adverse effects of
P. aeruginosa may be mitigated by exacerbation prevention. Furthermore, it highlights the important
impact of exacerbations in the non-Pseudomonas population, validating this as a key therapeutic target.
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